Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Bradley Norman Reames

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7575-7196; OpenAlex author ID A5019922677. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 16

  1. Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-026-01600-0↗
  2. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  3. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Morbidity and Mortality of Non-pancreatectomy operations for pancreatic cancer: An ACS-NSQIP analysis. First author DOI 10.1016/j.amjsurg.2022.08.012↗
  6. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  7. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2021.12.018↗
  8. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  9. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Last author DOI 10.1016/j.sopen.2022.07.007↗
  10. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-021-04984-5↗
  11. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? First author DOI 10.1016/j.ctro.2021.04.002↗
  12. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Co-author DOI 10.1097/sla.0000000000003568↗
  13. Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". Co-author DOI 10.1097/sla.0000000000004789↗
  14. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP. Last author DOI 10.1245/s10434-020-09460-z↗
  15. Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3684-2↗
  16. Pancreaticoduodenectomy with en bloc vein resection for locally advanced pancreatic cancer: a case series without venous reconstruction. First author DOI 10.21037/cco.2018.01.01↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aslam M. Ejaz · 6 shared papers, 2018–2026 · strength 0.96
  2. Chunmeng Zhang · 4 shared papers, 2022–2026 · strength 0.82
  3. Robert W. Krell · 4 shared papers, 2021–2023 · strength 0.73
  4. Matthew John Weiss · 4 shared papers, 2018–2022 · strength 0.56
  5. José Oberholzer · 2 shared papers, 2026 · strength 0.50
  6. Ning Pu · 2 shared papers, 2026 · strength 0.50
  7. Haleh Amirian · 2 shared papers, 2026 · strength 0.50
  8. Dilmurodjon Eshmuminov · 2 shared papers, 2026 · strength 0.50
  9. Víctor López‐López · 2 shared papers, 2026 · strength 0.50
  10. Michael C. Frey · 2 shared papers, 2026 · strength 0.50
  11. So Heun Lee · 2 shared papers, 2026 · strength 0.50
  12. Ralph Fritsch · 2 shared papers, 2026 · strength 0.50
  13. Changhoon Yoo · 2 shared papers, 2026 · strength 0.50
  14. Jashodeep Datta · 2 shared papers, 2026 · strength 0.50
  15. Chi H. Lin · 3 shared papers, 2021–2022 · strength 0.44
  16. Chandrakanth Are · 3 shared papers, 2021–2022 · strength 0.43
  17. Jin Peng He · 4 shared papers, 2018–2022 · strength 0.42
  18. Christopher Lee Wolfgang · 4 shared papers, 2018–2022 · strength 0.42
  19. Alex B. Blair · 3 shared papers, 2018–2022 · strength 0.34
  20. Michael J. Baine · 2 shared papers, 2021–2022 · strength 0.33
  21. Ziyi Zhou · 1 shared paper, 2026 · strength 0.32
  22. Eric David Miller · 1 shared paper, 2026 · strength 0.32
  23. Patrick L. Quinn · 1 shared paper, 2026 · strength 0.32
  24. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.32
  25. Alexandra M. Adams · 1 shared paper, 2023 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.